Back to search
FDAFDA · Food and drugs·Recall number D-0575-2025

Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-count bottle, Rx only, Distributed by: Pfizer Inc., New York, NY 10017, Made in Austria, NDC 60793-851-01.

Published August 20, 2025 · Recall initiated: July 29, 2025

Summary

FDA records drug Class II recall D-0575-2025, published August 20, 2025 and initiated July 29, 2025. Recalling firm: Pfizer; Status: Ongoing; Reported quantity: 29, 004 bottles; Lot: Lot #: 24C11, Exp 2/28/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent drug

What to do

Voluntary: Firm initiated · Letter

Get an email if LEVOXYL has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
LEVOXYL
Manufacturer
Pfizer
Distributor
Within U.S
UPC
0360793856018
Lot
Lot #: 24C11, Exp 2/28/2026.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-count bottle, Rx only, Distributed by: Pfizer Inc., New York, NY 10017, Made in Austria, NDC 60793-851-01. recalled?

Yes. FDA published recall D-0575-2025 on August 20, 2025. Reported hazard: Subpotent drug

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: LEVOXYL. UPC: 0360793856018.